What does multi-morbidity mean for cancer treatment and outcomes
Programme stream(s): Cancer control / living with and beyond and cancer outcomes , Prevention , Treatment
Programme session type(s): Specialist session
Presenter: Abdulqadr Akinoso-Imran, Queens University Belfast, UK
Presenter: Eilidh Fletcher, Information Services Division, NHS National Services Scotland, UK
Speaker: Alison Fielding, NCRI Consumer Forum, UK
Speaker: David Blane, University of Glasgow, UK
Speaker: Katriina Whitaker, University of Surrey, UK
Date and time: Sun 04-Nov-2018, 16:35-18:35
An ageing population means that cancer is increasingly diagnosed, treated and survived by older people with co-existing health conditions. This has major implications for diagnosing and treating cancer, and also for caring for cancer survivors in the longer term. In this session international experts will discuss key challenges and state-of-the art research findings with respect to how comorbidities can influence the initial diagnosis of cancer. We will also consider how primary care is meeting the challenge of managing people with cancer as well as other major health conditions. Crucially, the session will also consider how people with cancer experience and deal with comorbidity during their cancer journey.
– How do comorbidities influence the diagnosis, treatment and outcomes from cancer?
– How can patients with comorbidities best be supported during their cancer journey?
– What should be our policy and research priorities for comorbidity and cancer?
– Quantifying under-treatment in older adult lung cancer patients in Northern Ireland – Abdulqadr Akinsos-Imran
– Investigating common comorbidities in patients diagnosed with cancer– a Scottish Routes from Diagnosis analysis – Eilidh Fletcher